Skip Nav Destination
Issues
1 May 2011
-
Cover Image
Cover Image
Migration of hepatocellular carcinoma (HCC) cells that have undergone epithelial to mesenchymal transition (EMT). The 3sp cells transdifferentiated from malignant hepatocytes in the HCC patient via EMT show a migratory potential as determined by Platypus technology that can be modulated by pharmacological interference. Migrating cells are visualized by staining with CellTracker. For details, see article by van Zijl and colleagues on page 850. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
Highlights
Therapeutic Discovery
An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding
Jane Kendrew; Cath Eberlein; Brad Hedberg; Karen McDaid; Neil R. Smith; Hazel M. Weir; Stephen R. Wedge; David C. Blakey; Ian Foltz; Joe Zhou; Jaspal S. Kang; Simon T. Barry
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Maurizio Scaltriti; Violeta Serra; Emmanuel Normant; Marta Guzman; Olga Rodriguez; Alice R. Lim; Kelly L. Slocum; Kip A. West; Varenka Rodriguez; Ludmila Prudkin; José Jimenez; Claudia Aura; José Baselga
Preclinical Development
Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
Sandra R. Brave; Kirsty Ratcliffe; Zena Wilson; Neil H. James; Sue Ashton; Anna Wainwright; Jane Kendrew; Philippa Dudley; Nicola Broadbent; Graham Sproat; Sian Taylor; Claire Barnes; Jeffrey C. Silva; Charles L. Farnsworth; Laurent Hennequin; Donald J. Ogilvie; Juliane M. Jürgensmeier; Masabumi Shibuya; Stephen R. Wedge; Simon T. Barry
Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
Jianfeng Lu; Donna McEachern; Haiying Sun; Longchuan Bai; Yuefeng Peng; Su Qiu; Rebecca Miller; Jinhui Liao; Han Yi; Meilan Liu; Anita Bellail; Chunhai Hao; Shi-Yong Sun; Adrian T. Ting; Shaomeng Wang
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds